Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses hormonal therapies for acne related to endocrine disorders and provides practical guidelines for managing hormonally influenced acne in clinical practice, but reports no new clinical results.

This study found that estradiol affects hair growth in mice by regulating the transition of hair follicles from rest to growth phases via the estrogen receptor pathway in the dermal papilla.

This study found that cyclic MPA is as effective as OCPs in resuming ovulation among women with PCOS, offering a viable alternative for those who cannot or choose not to use OCPs.

This review discusses the diagnosis and treatment of hyperandrogenism in women, emphasizing that cyproterone acetate is effective for severe hirsutism, though it reports no new clinical findings.

This review examined various treatments for hirsutism and found low to very low quality evidence suggesting that flutamide and spironolactone may help reduce hair growth, while metformin was ineffective.

This study suggests spironolactone, particularly when combined with an oral contraceptive or dexamethasone, may reduce hair symptoms in women with hirsutism, but it should be avoided during pregnancy and in women with a family history of breast cancer.

This article is a commentary on another piece about the clinical efficacy of oral finasteride and reports no new results.

This study found that the combination of spironolactone and finasteride significantly improved hirsutism scores more than spironolactone alone in women, with similar side-effect profiles between treatments.

This study found that local synthesis of 17β-estradiol and 5α-dihydrotestosterone, combined with specific stimulation patterns, is crucial in determining the direction and strength of long-term synaptic effects in the hippocampal CA1 region of male rat slices.

This study found that six months of combined estrogen-progestin pill therapy led to a significant reduction in serum AMH levels and improvement in hyperandrogenic symptoms among women with PCOS.

This study found that both high-dose and low-dose finasteride significantly reduced hirsutism scores in women after 12 months, with the lower dose being safe and cost-effective.

This article discusses the complexities of androgen and antiandrogen therapies in women, detailing diagnostic measures, the effects on libido, and the potential benefits of new progestins with antiandrogenic properties, but presents no new empirical findings.

This study explored a method using deep solvents in the presence of ultrasound to efficiently extract lignans from flax seeds, aiming to maximize their health benefits like hormonal balance and reduced cancer risk, while minimizing toxicity.

This study explored the development of a self nanoemulsifying drug delivery system to enhance the solubility and oral bioavailability of exemestane HCl for breast cancer therapy.

In this randomized study, BAY 1158061, a prolactin receptor antibody, was found to be safe, well-tolerated, and exhibited low immunogenicity in healthy postmenopausal women, but had no effect on serum prolactin levels compared to placebo.

This study found that spironolactone at 200 mg/day effectively reduced facial hair growth in women with moderate to severe hirsutism, with improvements observed within two months and sustained over one year.

This review discusses skin diseases related to contraceptive use, reporting potential issues with oral contraceptives and infrequent reactions to mechanical or barrier methods without new clinical findings.

In this study, treatment with flutamide combined with a low-dose oral contraceptive significantly improved hirsutism in women with polycystic ovarian disease who did not respond to oral contraceptive treatment alone.

This study found that combining letrozole with metformin was more effective at inducing pregnancy in women with PCOS compared to letrozole alone, while OCP and metformin significantly improved menstrual regularity and reduced hyperandrogenic symptoms.

In this study, osthenol was identified as a highly potent inhibitor of 5alpha-reductase type I in LNCaP cells, significantly outperforming finasteride.

This review discusses the diagnosis, management, and hormone treatment of transsexual individuals, and examines the risks and effects of cross-sex hormone therapy without presenting new clinical results.

This study reports that five new progesterone derivatives demonstrated inhibitory activity against the 5α-reductase enzyme and binding affinity for the androgen receptor in an in vitro hamster model.

This study suggests that estrogen synthesis from estrone sulfate significantly influences hair growth regulation, with variations based on the hair growth phase, gender, and age.

In this pilot study, finasteride increased testosterone/dihydrotestosterone and progesterone/dihydroprogesterone ratios in normal ovulatory women but did not alter ovulation or gonadotropin secretion.

This study reports that two oral hormonal agents, dimethandrolone undecanoate and 11β-methylnortestosterone dodecylcarbonate, may effectively suppress hormones to contraceptive levels in men with mild side effects, though longer-term trials are required to confirm their safety and efficacy.

This study determined the crystal structure and conformation of synthesized 17x-Acetoxy-pregn-4,6-diene-3,20-dione, revealing specific molecular interactions and structural details in an orthorhombic crystal system.

This study found that GnRH agonist treatment improved hirsutism scores more than finasteride after six months in women with idiopathic hirsutism, with both treatments causing no menstrual abnormalities or side-effects.

In this study, content analysis of German YouTube videos revealed that women frequently experience both positive and negative symptoms related to oral contraceptive use and discontinuation, with bodily sensations often influencing their decisions to start or stop the pill.